When people talk about generic vaccines, they’re imagining something like generic pills-cheaper, widely available, and easy to copy. But vaccines aren’t pills. They’re not chemical compounds you can reverse-engineer in a lab. They’re biologics-living, complex molecules made from cells, viruses, or proteins. And that changes everything about how they’re made, who can make them, and who gets them.
Why There’s No Such Thing as a ‘Generic Vaccine’
You can’t just copy a vaccine the way you copy a painkiller. A generic ibuprofen tablet has the same active ingredient, same dosage, same effect. But a vaccine? It’s not just about the ingredient. It’s about how it’s grown, purified, stabilized, and delivered. Take mRNA vaccines like Pfizer’s or Moderna’s. They need lipid nanoparticles to protect the fragile genetic material. Those lipids? Only five or seven companies worldwide can make them at the scale and purity required. If you don’t have access to those, you can’t make the vaccine-even if you have the recipe.
The U.S. FDA doesn’t even have a shortcut process for vaccines like it does for small-molecule drugs. For regular drugs, manufacturers can use the Abbreviated New Drug Application (ANDA) to prove bioequivalence. But vaccines? You need a full Biological License Application. That means starting from scratch: testing every batch, proving safety, validating every step of production. It’s not a matter of copying. It’s a matter of rebuilding.
The Manufacturing Maze: Cold Chains, Containment, and Capital
Building a vaccine factory isn’t like building a drug plant. It requires biosafety level 2 or 3 labs. Temperature-controlled rooms. Ultra-cold freezers for mRNA vaccines that need -70°C. Specialized equipment for cell culture, filtration, and formulation. Each batch can take six to twelve months to produce. And the cost? A single production line can run over $500 million. That’s not a startup expense. That’s a national infrastructure project.
India’s Serum Institute of India (SII) is the world’s largest vaccine manufacturer by volume. It produces 1.5 billion doses a year across 11 facilities. But even SII couldn’t keep up during the pandemic. When global demand hit 11 billion doses, it was like trying to fill a swimming pool with a garden hose. And SII’s biggest challenge wasn’t capacity-it was supply. Nearly 70% of its raw materials, from cell culture media to lipid nanoparticles, come from China and Europe. When the U.S. restricted exports of those materials during India’s 2021 surge, global vaccine production dropped by half.
Who Makes the World’s Vaccines? And Who Gets Them?
Five companies-GSK, Merck, Sanofi, Pfizer, and Johnson & Johnson-controlled 70% of the $38 billion global vaccine market in 2020. They’re not just big. They’re entrenched. Their patents, supply chains, and regulatory relationships create a moat no new player can easily cross.
Meanwhile, India produces 60% of the world’s vaccine volume. It supplies 90% of the WHO’s measles vaccines, 70% of its DPT, and 40-70% of its BCG. But here’s the twist: Africa imports 99% of its vaccines. Despite being home to the world’s largest vaccine manufacturer, the continent produces less than 2% of its own needs. In 2021, 83% of the 1.1 million COVID-19 doses delivered to Africa through COVAX went to just 10 countries. Twenty-three African nations had vaccinated fewer than 2% of their people.
It’s not a shortage of skill. It’s a shortage of control. Indian manufacturers make vaccines for the world, but they don’t decide who gets them. High-income countries pre-bought 86% of the first COVID-19 doses. Low-income countries waited months. In the Democratic Republic of Congo, health workers received doses expiring in two weeks-with no cold chain to store them.
Technology Transfer: Promises vs. Reality
The WHO set up a technology transfer hub in South Africa in 2021, partnering with BioNTech to teach African manufacturers how to make mRNA vaccines. The goal? Local production. The reality? Eighteen months later, they were still struggling to source the right equipment. Lipid nanoparticles. Bioreactors. Precision filling machines. Many of these aren’t sold on open markets. They’re locked behind long-term contracts with a handful of suppliers.
Even when the tech is shared, the materials aren’t. Dr. Gagandeep Kang from Christian Medical College Vellore put it plainly: India has 500 API manufacturers, but imports 70% of its vaccine raw materials from China. Without control over inputs, you can’t control output.
The African Union estimates it will take $4 billion and 10 years to get Africa to 60% self-sufficiency. That’s not impossible. But it’s not happening fast enough. Meanwhile, the U.S. FDA launched a pilot in 2025 to fast-track generic drug approvals for manufacturers based in the U.S.-a move that highlights how deeply countries are now thinking about supply chain security. But for vaccines? No such program exists for low-income countries.
Price Isn’t the Problem-Power Is
Some argue that if only vaccines were cheaper, access would improve. But the problem isn’t price alone. It’s pricing power.
Generic drugs can drop 80-90% in price after a few competitors enter the market. Vaccines? Not so much. Gavi, the Vaccine Alliance, reported that even after pressure, the pneumococcal conjugate vaccine cost low-income countries over $10 per dose-while Western manufacturers sold it for $15-20. SII made the AstraZeneca vaccine for $3-4 per dose. But that wasn’t profit. It was barely enough to cover costs. No manufacturer, even one as large as SII, can afford to build a $500 million facility and operate on pennies per dose.
And when export restrictions hit-like when India halted vaccine exports in April 2021 during its second wave-global supply shrank overnight. The world learned a hard lesson: vaccine production isn’t a global public good. It’s a national priority.
What’s Next? Can Equity Be Built?
The mRNA hub in South Africa produced its first vaccines in September 2023. A milestone. But its capacity? 100 million doses a year. Global demand? Over 4 billion. That’s less than 2.5% of need.
There are models for change. SII proved that high-volume, low-margin production works. BioNTech and Moderna showed how innovation can scale fast. Oxford’s partnership with AstraZeneca proved that non-profit licensing can accelerate access. But these aren’t systems. They’re exceptions.
True equity won’t come from charity. It won’t come from donations. It will come from building local capacity-with real investment, real technology transfer, and real control over supply chains. Until then, the world will keep facing the same crisis: the people who need vaccines the most are the last to get them-not because they’re not made, but because they’re not owned.
